Regeneron Pharmaceuticals, Inc. (BVL:REGN)

Regeneron Pharmaceuticals Statistics

Total Valuation

BVL:REGN has a market cap or net worth of PEN 209.76 billion. The enterprise value is 157.79 billion.

Market Cap	209.76B
Enterprise Value	157.79B

Important Dates

The next estimated earnings date is Monday, November 3, 2025.

Earnings Date	Nov 3, 2025
Ex-Dividend Date	Aug 18, 2025

Share Statistics

Current Share Class	101.87M
Shares Outstanding	n/a
Shares Change (YoY)	-1.75%
Shares Change (QoQ)	-2.34%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	97.89M

Valuation Ratios

The trailing PE ratio is 13.29 and the forward PE ratio is 14.17.

PE Ratio	13.29
Forward PE	14.17
PS Ratio	4.17
PB Ratio	1.98
P/TBV Ratio	2.07
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.99, with an EV/FCF ratio of 11.57.

EV / Earnings	10.00
EV / Sales	3.17
EV / EBITDA	9.99
EV / EBIT	11.37
EV / FCF	11.57

Financial Position

The company has a current ratio of 4.60, with a Debt / Equity ratio of 0.09.

Current Ratio	4.60
Quick Ratio	3.57
Debt / Equity	0.09
Debt / EBITDA	0.60
Debt / FCF	0.70
Interest Coverage	108.11

Financial Efficiency

Return on equity (ROE) is 15.34% and return on invested capital (ROIC) is 7.78%.

Return on Equity (ROE)	15.34%
Return on Assets (ROA)	6.66%
Return on Invested Capital (ROIC)	7.78%
Return on Capital Employed (ROCE)	11.45%
Revenue Per Employee	3.31M
Profits Per Employee	1.04M
Employee Count	15,106
Asset Turnover	0.38
Inventory Turnover	2.46

Taxes

In the past 12 months, BVL:REGN has paid 1.47 billion in taxes.

Income Tax	1.47B
Effective Tax Rate	8.54%

Stock Price Statistics

The stock price has decreased by -43.87% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-43.87%
50-Day Moving Average	648.13
200-Day Moving Average	763.95
Relative Strength Index (RSI)	38.10
Average Volume (20 Days)	2

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.03

Income Statement

In the last 12 months, BVL:REGN had revenue of PEN 50.32 billion and earned 15.78 billion in profits. Earnings per share was 140.44.

Revenue	50.32B
Gross Profit	23.82B
Operating Income	14.01B
Pretax Income	17.26B
Net Income	15.78B
EBITDA	15.81B
EBIT	14.01B
Earnings Per Share (EPS)	140.44

Balance Sheet

The company has 26.44 billion in cash and 9.58 billion in debt, giving a net cash position of 52.47 billion.

Cash & Cash Equivalents	26.44B
Total Debt	9.58B
Net Cash	52.47B
Net Cash Per Share	n/a
Equity (Book Value)	105.98B
Book Value Per Share	1,017.87
Working Capital	46.70B

Cash Flow

In the last 12 months, operating cash flow was 16.79 billion and capital expenditures -3.15 billion, giving a free cash flow of 13.64 billion.

Operating Cash Flow	16.79B
Capital Expenditures	-3.15B
Free Cash Flow	13.64B
FCF Per Share	n/a

Margins

Gross margin is 47.35%, with operating and profit margins of 27.84% and 31.37%.

Gross Margin	47.35%
Operating Margin	27.84%
Pretax Margin	34.30%
Profit Margin	31.37%
EBITDA Margin	31.42%
EBIT Margin	27.84%
FCF Margin	27.11%

Dividends & Yields

This stock pays an annual dividend of 9.64, which amounts to a dividend yield of 1.62%.

Dividend Per Share	9.64
Dividend Yield	1.62%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	4.18%
Buyback Yield	1.75%
Shareholder Yield	3.36%
Earnings Yield	7.52%
FCF Yield	6.50%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BVL:REGN has an Altman Z-Score of 8.61 and a Piotroski F-Score of 4.

Altman Z-Score	8.61
Piotroski F-Score	4